Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study.

Taieb J, Prager GW, Melisi D, Westphalen CB, D'Esquermes N, Ferreras A, Carrato A, Macarulla T.

ESMO Open. 2020 Jan;5(1). pii: e000587. doi: 10.1136/esmoopen-2019-000587.

2.

Fibroblast-Derived 3D Matrix System Applicable to Endothelial Tube Formation Assay.

Galindo-Pumariño C, Herrera A, Muñoz A, Carrato A, Herrera M, Peña C.

J Vis Exp. 2019 Dec 26;(154). doi: 10.3791/60304.

PMID:
31929503
3.

Diesel exhaust and bladder cancer risk by pathologic stage and grade subtypes.

Koutros S, Kogevinas M, Friesen MC, Stewart PA, Baris D, Karagas MR, Schwenn M, Johnson A, Monawar Hosain GM, Serra C, Tardon A, Carrato A, Garcia-Closas R, Moore LE, Nickerson ML, Hewitt SM, Lenz P, Schned AR, Lloreta J, Allory Y, Zhang H, Chatterjee N, Garcia-Closas M, Rothman N, Malats N, Silverman DT.

Environ Int. 2020 Feb;135:105346. doi: 10.1016/j.envint.2019.105346. Epub 2019 Dec 18.

4.

Survey of treatment recommendations for elderly patients with glioblastoma.

Vaz Salgado MA, Torres J, Esteban J, Gutiérrez JA, Ley L, Carrato A.

Clin Transl Oncol. 2019 Dec 20. doi: 10.1007/s12094-019-02260-2. [Epub ahead of print]

PMID:
31863352
5.

Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials.

Benavides M, Díaz-Rubio E, Carrato A, Abad A, Guillén C, Garcia-Alfonso P, Gil S, Cano MT, Safont MJ, Gravalos C, Manzano JL, Sánchez A, Alcaide J, López R, Massutí B, Sastre J, Martínez E, Escudero P, Méndez M, Aranda E.

ESMO Open. 2019 Dec 1;4(6):e000599. doi: 10.1136/esmoopen-2019-000599. eCollection 2019. Erratum in: ESMO Open. 2020 Jan;5(1):.

6.

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.

Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium.

Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31.

PMID:
31672839
7.

Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms.

Pozas J, San Román M, Alonso-Gordoa T, Pozas M, Caracuel L, Carrato A, Molina-Cerrillo J.

Int J Mol Sci. 2019 Oct 8;20(19). pii: E4949. doi: 10.3390/ijms20194949. Review.

8.

Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts.

Camps Herrero C, Antón Torres A, Cruz-Hernández JJ, Carrato A, Constenla M, Díaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascón P, Guillem V.

J Pain Res. 2019 Jul 29;12:2349-2358. doi: 10.2147/JPR.S203903. eCollection 2019.

9.

The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care.

Kerr D, Arnold D, Blay JY, Buske C, Carrato A, Gerritsen W, Peeters M.

Oncologist. 2020 Jan;25(1):e1-e4. doi: 10.1634/theoncologist.2019-0337. Epub 2019 Sep 5. No abstract available.

10.

Author's reply to: Air pollution and incident bladder cancer: A risk assessment.

Turner MC, Gracia-Lavedan E, Cirac M, Castaño-Vinyals G, Malats N, Tardon A, Garcia-Closas R, Serra C, Carrato A, Jones RR, Rothman N, Silverman DT, Kogevinas M.

Int J Cancer. 2019 Dec 1;145(11):3178. doi: 10.1002/ijc.32632. Epub 2019 Aug 30. No abstract available.

PMID:
31423586
11.

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.

Elez E, Pericay C, Valladares-Ayerbes M, Bando I, Safont MJ, Gallego J, Grávalos C, Arrivi A, Carrato A, Conde V, Ortiz MJ, López C, Alonso B, Ruiz de Mena I, Díaz-Rubio E, Tabernero J, Aranda E.

Br J Cancer. 2019 Aug;121(5):378-383. doi: 10.1038/s41416-019-0537-z. Epub 2019 Jul 31.

12.

Safety and Oncological Outcomes of Bevacizumab Therapy in Patients With Advanced Colorectal Cancer and Self-expandable Metal Stents.

Pacheco-Barcia V, Mondéjar R, Martínez-Sáez O, Longo F, Moreno JA, Rogado J, Donnay O, Santander C, Carrato A, Colomer R.

Clin Colorectal Cancer. 2019 Sep;18(3):e287-e293. doi: 10.1016/j.clcc.2019.05.009. Epub 2019 Jun 8.

PMID:
31262698
13.

Incidental findings in pancreas screening programs for high-risk individuals: Results from three European expert centers.

Ibrahim IS, Brückner C, Carrato A, Earl J, Inderson A, de Vos Tot Nederveen Cappel WH, Mintziras I, Matthäi E, Figiel J, Wasser M, Moreau H, Bonsing B, Slater EP, Bartsch DK, Vasen HF.

United European Gastroenterol J. 2019 Jun;7(5):682-688. doi: 10.1177/2050640619841989. Epub 2019 Mar 31.

14.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E.

BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7.

15.

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer Patients.

Mezquita L, Benito A, Ruano-Raviña A, Zamora J, Olmedo ME, Reguera P, Madariaga A, Villamayor M, Cortez SP, Gorospe L, Santón A, Mayoralas S, Hernanz R, Cabañero A, Auclin E, Carrato A, Garrido P.

Clin Lung Cancer. 2019 Jul;20(4):305-312.e3. doi: 10.1016/j.cllc.2019.04.009. Epub 2019 May 3.

PMID:
31151782
16.

New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?

Barquín-García A, Molina-Cerrillo J, Garrido P, Garcia-Palos D, Carrato A, Alonso-Gordoa T.

Eur J Intern Med. 2019 Aug;66:1-8. doi: 10.1016/j.ejim.2019.05.020. Epub 2019 May 23. Review.

PMID:
31130304
17.

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys".

Alonso-Gordoa T, García-Bermejo ML, Grande E, Garrido P, Carrato A, Molina-Cerrillo J.

Int J Mol Sci. 2019 Apr 17;20(8). pii: E1901. doi: 10.3390/ijms20081901. Review.

18.

Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.

D'Errico G, Alonso-Nocelo M, Vallespinos M, Hermann PC, Alcalá S, García CP, Martin-Hijano L, Valle S, Earl J, Cassiano C, Lombardia L, Feliu J, Monti MC, Seufferlein T, García-Bermejo L, Martinelli P, Carrato A, Sainz B Jr.

Oncogene. 2019 Jul;38(27):5469-5485. doi: 10.1038/s41388-019-0803-9. Epub 2019 Apr 1.

PMID:
30936462
19.

Screening of Individuals at High Risk for Pancreatic Cancer.

Vasen HFA, Bartsch DK, Carrato A.

Clin Gastroenterol Hepatol. 2019 Aug;17(9):1916-1917. doi: 10.1016/j.cgh.2019.03.023. Epub 2019 Mar 19. No abstract available.

PMID:
30902598
20.

Novel Molecular Characterization of Colorectal Primary Tumors Based on miRNAs.

Moreno EC, Pascual A, Prieto-Cuadra D, Laza VF, Molina-Cerrillo J, Ramos-Muñoz ME, Rodríguez-Serrano EM, Soto JL, Carrato A, García-Bermejo ML, Guillén-Ponce C.

Cancers (Basel). 2019 Mar 11;11(3). pii: E346. doi: 10.3390/cancers11030346.

21.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Vidal J, Bellosillo B, Santos Vivas C, García-Alfonso P, Carrato A, Cano MT, García-Carbonero R, Élez E, Losa F, Massutí B, Valladares-Ayerbes M, Viéitez JM, Manzano JL, Azuara D, Gallego J, Pairet S, Capellá G, Salazar R, Tabernero J, Aranda E, Montagut C.

Ann Oncol. 2019 Mar 1;30(3):439-446. doi: 10.1093/annonc/mdz005.

PMID:
30689692
22.

Ambient air pollution and incident bladder cancer risk: Updated analysis of the Spanish Bladder Cancer Study.

Turner MC, Gracia-Lavedan E, Cirac M, Castaño-Vinyals G, Malats N, Tardon A, Garcia-Closas R, Serra C, Carrato A, Jones RR, Rothman N, Silverman DT, Kogevinas M.

Int J Cancer. 2019 Aug 15;145(4):894-900. doi: 10.1002/ijc.32136. Epub 2019 Feb 8.

PMID:
30653254
23.

A Label Free Disposable Device for Rapid Isolation of Rare Tumor Cells from Blood by Ultrasounds.

González I, Earl J, Fernández LJ, Sainz B, Pinto A, Monge R, Alcalá S, Castillejo A, Soto JL, Carrato A.

Micromachines (Basel). 2018 Mar 15;9(3). pii: E129. doi: 10.3390/mi9030129.

24.

Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker.

Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M, Oldfield L, Neoptolemos JP, Greenhalf W, Earl J, Carrato A, Costello E, Navarro P.

Oncotarget. 2018 Aug 31;9(68):32984-32996. doi: 10.18632/oncotarget.26034. eCollection 2018 Aug 31.

25.

Endothelial cell activation on 3D-matrices derived from PDGF-BB-stimulated fibroblasts is mediated by Snail1.

Herrera A, Herrera M, Guerra-Perez N, Galindo-Pumariño C, Larriba MJ, García-Barberán V, Gil B, Giménez-Moyano S, Ferreiro-Monteagudo R, Veguillas P, Candia A, Peña R, Pinto J, García-Bermejo ML, Muñoz A, García de Herreros A, Bonilla F, Carrato A, Peña C.

Oncogenesis. 2018 Sep 24;7(9):76. doi: 10.1038/s41389-018-0085-z.

26.

Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches.

Gomez-Rubio P, Piñero J, Molina-Montes E, Gutiérrez-Sacristán A, Marquez M, Rava M, Michalski CW, Farré A, Molero X, Löhr M, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Balsells J, Costello E, Yu J, Iglesias M, Ilzarbe L, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Lawlor RT, Ye W, Hidalgo M, Scarpa A, Sharp L, Carrato A, Real FX, Furlong LI, Malats N; PanGenEU Study Investigators.

Int J Cancer. 2019 Apr 1;144(7):1540-1549. doi: 10.1002/ijc.31866. Epub 2018 Oct 26.

PMID:
30229903
27.

Differential distribution and enrichment of non-coding RNAs in exosomes from normal and Cancer-associated fibroblasts in colorectal cancer.

Herrera M, Llorens C, Rodríguez M, Herrera A, Ramos R, Gil B, Candia A, Larriba MJ, Garre P, Earl J, Rodríguez-Garrote M, Caldés T, Bonilla F, Carrato A, García-Barberán V, Peña C.

Mol Cancer. 2018 Aug 3;17(1):114. doi: 10.1186/s12943-018-0863-4.

28.

Management and supportive treatment of frail patients with metastatic pancreatic cancer.

Macarulla T, Carrato A, Díaz R, García A, Laquente B, Sastre J, Álvarez R, Muñoz A, Hidalgo M.

J Geriatr Oncol. 2019 May;10(3):398-404. doi: 10.1016/j.jgo.2018.06.005. Epub 2018 Jul 11. Review.

PMID:
30005980
29.

From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.

Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A.

J Cancer. 2018 Apr 30;9(11):1978-1988. doi: 10.7150/jca.23716. eCollection 2018. Review.

30.

A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer.

Grávalos C, Carrato A, Tobeña M, Rodriguez-Garrote M, Soler G, Vieitez JM, Robles L, Valladares-Ayerbes M, Polo E, Limón ML, Safont MJ, Martínez de Castro E, García-Alfonso P, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).

Clin Colorectal Cancer. 2018 Jun;17(2):e323-e329. doi: 10.1016/j.clcc.2018.02.004. Epub 2018 Feb 17.

PMID:
29551560
31.

Management of hyperbilirubinaemia in pancreatic cancer patients.

Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, Macarulla T, Muñoz A, Hidalgo M.

Eur J Cancer. 2018 May;94:26-36. doi: 10.1016/j.ejca.2018.01.078. Epub 2018 Mar 20. Review.

PMID:
29505968
32.

Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives.

Molina-Montes E, Gomez-Rubio P, Márquez M, Rava M, Löhr M, Michalski CW, Molero X, Farré A, Perea J, Greenhalf W, Ilzarbe L, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Balsells J, Costello E, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Poves I, Scarpa A, Ye W, Hidalgo M, Sharp L, Carrato A, Real FX, Malats N; PanGenEU Study Investigators.

Int J Epidemiol. 2018 Apr 1;47(2):473-483. doi: 10.1093/ije/dyx269.

PMID:
29329392
33.

Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR).

Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z.

PMID:
29243205
34.

Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.

Huang L, Jansen L, Balavarca Y, Molina-Montes E, Babaei M, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, Johannesen TB, Fristrup CW, Mortensen MB, Primic-Žakelj M, Zadnik V, Becker N, Hackert T, Mägi M, Cassetti T, Sassatelli R, Grützmann R, Merkel S, Gonçalves AF, Bento MJ, Hegyi P, Lakatos G, Szentesi A, Moreau M, van de Velde T, Broeks A, Sant M, Minicozzi P, Mazzaferro V, Real FX, Carrato A, Molero X, Besselink MG, Malats N, Büchler MW, Schrotz-King P, Brenner H.

Gut. 2019 Jan;68(1):130-139. doi: 10.1136/gutjnl-2017-314828. Epub 2017 Nov 20.

PMID:
29158237
35.

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial.

Abad A, Martínez-Balibrea E, Viéitez JM, Alonso-Orduña V, García Alfonso P, Manzano JL, Massutí B, Benavides M, Carrato A, Zanui M, Gallego J, Grávalos C, Conde V, Provencio M, Valladares-Ayerbes M, Salazar R, Sastre J, Montagut C, Rivera F, Aranda E.

Ann Oncol. 2018 Feb 1;29(2):439-444. doi: 10.1093/annonc/mdx737.

36.

A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.

Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR).

Target Oncol. 2018 Feb;13(1):69-78. doi: 10.1007/s11523-017-0536-z. Erratum in: Target Oncol. 2017 Dec 14;:.

PMID:
29128908
37.

Asthma status is associated with decreased risk of aggressive urothelial bladder cancer.

Rava M, Czachorowski MJ, Silverman D, Márquez M, Kishore S, Tardón A, Serra C, García-Closas M, Garcia-Closas R, Carrato A, Rothman N, Real FX, Kogevinas M, Malats N.

Int J Cancer. 2018 Feb 1;142(3):470-476. doi: 10.1002/ijc.31066. Epub 2017 Oct 16.

38.

Surgery for pancreatic ductal adenocarcinoma.

Vera R, Díez L, Martín Pérez E, Plaza JC, Sanjuanbenito A, Carrato A.

Clin Transl Oncol. 2017 Nov;19(11):1303-1311. doi: 10.1007/s12094-017-1688-0. Epub 2017 Jun 23. Review.

PMID:
28646282
39.

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).

Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).

Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19.

40.

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.

Santos C, Azuara D, Garcia-Carbonero R, Alfonso PG, Carrato A, Elez ME, Gomez A, Losa F, Montagut C, Massuti B, Navarro V, Varela M, Lopez-Doriga A, Moreno V, Valladares M, Manzano JL, Vieitez JM, Aranda E, Sanjuan X, Tabernero J, Capella G, Salazar R.

Mol Cancer Ther. 2017 Sep;16(9):1999-2007. doi: 10.1158/1535-7163.MCT-17-0153. Epub 2017 Jun 16.

41.

Biomarkers in pancreatic ductal adenocarcinoma.

Gallego J, López C, Pazo-Cid R, López-Ríos F, Carrato A.

Clin Transl Oncol. 2017 Dec;19(12):1430-1437. doi: 10.1007/s12094-017-1691-5. Epub 2017 Jun 14. Review.

PMID:
28616721
42.

Supportive care in pancreatic ductal adenocarcinoma.

Laquente B, Calsina-Berna A, Carmona-Bayonas A, Jiménez-Fonseca P, Peiró I, Carrato A.

Clin Transl Oncol. 2017 Nov;19(11):1293-1302. doi: 10.1007/s12094-017-1682-6. Epub 2017 Jun 13. Review.

PMID:
28612201
43.

Diagnosis and staging of pancreatic ductal adenocarcinoma.

Guillén-Ponce C, Blázquez J, González I, de-Madaria E, Montáns J, Carrato A.

Clin Transl Oncol. 2017 Oct;19(10):1205-1216. doi: 10.1007/s12094-017-1681-7. Epub 2017 Jun 13. Review.

PMID:
28612200
44.

A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk.

Gomez-Rubio P, Rosato V, Márquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberá VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong LI, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators.

Ann Oncol. 2017 Jul 1;28(7):1618-1624. doi: 10.1093/annonc/mdx167.

45.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.

Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

J Clin Oncol. 2017 Feb;35(4):446-464. doi: 10.1200/JCO.2016.69.4836. Epub 2016 Nov 14.

PMID:
28129524
46.

Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib.

Cebrián A, Gómez Del Pulgar T, Méndez-Vidal MJ, Gonzálvez ML, Lainez N, Castellano D, García-Carbonero I, Esteban E, Sáez MI, Villatoro R, Suárez C, Carrato A, Munárriz-Ferrándiz J, Basterrechea L, García-Alonso M, González-Larriba JL, Perez-Valderrama B, Cruz-Jurado J, González Del Alba A, Moreno F, Reynés G, Rodríguez-Remírez M, Boni V, Mahillo-Fernández I, Martin Y, Viqueira A, García-Foncillas J.

Sci Rep. 2017 Jan 24;7:41371. doi: 10.1038/srep41371.

47.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Am J Clin Pathol. 2016 Dec;146(6):647-669. doi: 10.1093/ajcp/aqw206. Epub 2016 Nov 14. Review.

48.

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

Hidalgo M, Álvarez R, Gallego J, Guillén-Ponce C, Laquente B, Macarulla T, Muñoz A, Salgado M, Vera R, Adeva J, Alés I, Arévalo S, Blázquez J, Calsina A, Carmona A, de Madaria E, Díaz R, Díez L, Fernández T, de Paredes BG, Gallardo ME, González I, Hernando O, Jiménez P, López A, López C, López-Ríos F, Martín E, Martínez J, Martínez A, Montans J, Pazo R, Plaza JC, Peiró I, Reina JJ, Sanjuanbenito A, Yaya R, Carrato A.

Clin Transl Oncol. 2017 Jun;19(6):667-681. doi: 10.1007/s12094-016-1594-x. Epub 2016 Dec 19.

49.

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA.

Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363. Epub 2016 Nov 14.

PMID:
27841667
50.

Erratum to: The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, Real FX.

BMC Genomics. 2016 Oct 25;17(1):829. No abstract available.

Supplemental Content

Loading ...
Support Center